

WE WORK FOR HEALTH

MAJOR MILESTONE: U.S. Life Sciences Investments Top $500B+

Biopharmaceutical companies are continuing to invest big in America – and have pledged more than **$582 billion in 2025 alone** to strengthen future discovery and delivery of life-altering treatments for U.S. patients while reinforcing America's leadership in a strategically important sector. The life sciences industry supports **more than 4.9 million jobs**, including **356K+ in New Jersey** as of 2022.

IN NEW JERSEY

- A $3.5 billion upgrade of **Merck**'s headquarters in Rahway
- **Roche's** expansion of existing facilities
- Expansion of a **Novartis** manufacturing facility in Millburn
- New and expanded generic manufacturing capabilities by **Hikima** in Cherry Hill and Dayton
- A brand new, $130 million headquarters for **Sanofi** in Morristown

Congress: Protect America's Position As the World Leader in Life Sciences

Continued sector investment requires a policy environment that encourages innovation and protects American jobs. Global competitors, including China, are closing the gap.

Drug pricing policies like Most Favored Nation threaten America's biotech revolution.

230+ fewer new medicines over 10 years

1.1 million lost jobs

Surrender competitive edge to **China**

Fail to lower patient costs or address the real drivers of rising healthcare costs

Stay up-to-date on the latest life sciences' investment announcements and state-specific industry impact at weworkforhealth.org/investinamerica and weworkforhealth.org/in-the-states.

LEARN MORE AT WEWORKFORHEALTH.ORG